The study will include 5 treatment arms including 1 Placebo Arm and 4 active drug arms. Participants will be randomly selected to 1 of 5 arms.~Placebo~OCE-205 at 8 micrograms per hour (µg/hr)~OCE-205 at 15 micrograms per hour (µg/hr)~OCE-205 at 30 micrograms per hour (µg/hr)~OCE-205 at 50 micrograms per hour (µg/hr)~This multi-center trial will be conducted in the United States and Canada. If selected for the study, participants will be randomly assigned to 1 of the 5 treatment arms.
OCE-205 is being tested to treat participants who have developed Hepatorenal Syndrome-Acute Kidney Injury as a complication of cirrhosis with ascites.~The study aims are to evaluate the safety and efficacy of OCE-205 at various doses.~Participants will receive treatment by intravenous infusion. Participants will continue with this treatment until participants meets primary endpoint or any discontinuation criteria.